{"id":745523,"date":"2017-07-17T06:00:00","date_gmt":"2017-07-17T06:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentations-of-clinical-and-real-world-data-at-the-alzheimers-association-international-conference\/"},"modified":"2025-11-07T01:26:24","modified_gmt":"2025-11-07T06:26:24","slug":"merck-announces-presentations-of-clinical-and-real-world-data-at-the-alzheimers-association-international-conference","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentations-of-clinical-and-real-world-data-at-the-alzheimers-association-international-conference\/","title":{"rendered":"Merck Announces Presentations of Clinical and Real-World Data at The Alzheimer\u2019s Association International Conference\u00ae"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside of the United States and Canada,<br \/>\n      today announced the presentation of data at The Alzheimer\u2019s Association<br \/>\n      International Conference taking place in London, July 16\u201320, 2017.\n    <\/p>\n<p>\n      &#8220;Alzheimer\u2019s disease remains one of the most daunting medical issues of<br \/>\n      our time \u2013for individuals and their families, for the scientific and<br \/>\n      medical communities, and for public health,\u201d said Darryle Schoepp, vice<br \/>\n      president, neuroscience discovery, Merck Research Laboratories. &#8220;Merck<br \/>\n      has extensive research underway to develop novel medicines for<br \/>\n      Alzheimer\u2019s disease, and to improve understanding of the science and<br \/>\n      impact of this devastating disease.&#8221;\n    <\/p>\n<p>\n      Notable abstracts to be presented at The Alzheimer\u2019s Association<br \/>\n      International Conference<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup> include:\n    <\/p>\n<p>\n      <i>Saturday, July 15<\/i>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        First Evaluation of the Neurofibrillary Tangles Radioligand<br \/>\n        [18F]MK-6240 in AD Patients (Poster presentation, Abstract IC-P-177,<br \/>\n        12:15 p.m. \u2013 1:30 p.m. BST)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In Vitro Binding Studies to Evaluate the NFT-Specificity of [<sup>3<\/sup>H]MK-6240<br \/>\n        and [<sup>3<\/sup>H]AV-1451 Binding in Subcortical Regions of Human AD<br \/>\n        Brain (Poster presentation, Abstract IC-P-207, 12:15 p.m. \u2013 1:30 p.m.<br \/>\n        BST)\n      <\/li>\n<\/ul>\n<p>\n      <i>Sunday, July 16<\/i>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        The Race to Diagnose: Disease Severity As a Factor of AD Diagnosis<br \/>\n        (Poster presentation, Abstract P1-565, 9:30 a.m. \u2013 4:15 p.m. BST)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Episode of Care Among AD Patients Newly Diagnosed in Inpatient Setting<br \/>\n        in the U.S. Medicare Population (Poster presentation, Abstract P1-590,<br \/>\n        9:30 a.m. \u2013 4:15 p.m. BST)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Systems Pharmacology Analysis of the A\u03b2 Oligomer Response Following<br \/>\n        BACE1 Inhibition: Evidence for Second-Order A\u03b242 Oligomerization<br \/>\n        (Poster presentation, Abstract P1-108, 9:30 a.m. \u2013 4:15 p.m. BST)\n      <\/li>\n<\/ul>\n<p>\n      <i>Monday, July 17<\/i>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Comparison of Healthcare Costs for AD Patients Diagnosed in Inpatient<br \/>\n        Versus Non-Inpatient Setting (Poster presentation, Abstract P2-558,<br \/>\n        9:30 a.m. \u2013 4:15 p.m. BST)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Health Care Use Among Newly Diagnosed AD Patients in a U.S. Commercial<br \/>\n        Medicare Advantage Insurance Plan (Poster presentation, Abstract<br \/>\n        P2-557, 9:30 a.m. \u2013 4:15 p.m. BST)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Resilience Mechanism of the Amyloid Precursor Protein (APP) Pathway<br \/>\n        Revealed By Systems Pharmacology Modeling Following \u03b2- and \u03b3-Secretase<br \/>\n        Inhibition (Poster presentation, Abstract P2-066, 9:30 a.m. \u2013 4:15<br \/>\n        p.m. BST)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Acute Administration of a BACE Inhibitor in Healthy Humans Results in<br \/>\n        a Significant Reduction of A\u03b2 Oligomers in Cerebrospinal Fluid (Oral<br \/>\n        presentation, Abstract O2-09-01, 2:00 p.m. \u2013 2:15 p.m. BST)\n      <\/li>\n<\/ul>\n<p>\n      <i>Tuesday, July 18<\/i>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Phenotypic Screening for Novel Inhibitors of Tau Aggregation in Human<br \/>\n        iPSC-Derived Neurons (Poster presentation, P3-083, 9:30 a.m. \u2013 4:15<br \/>\n        p.m. BST)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Real-World Administration of the AD Assessment Scale-Cognitive (Poster<br \/>\n        presentation, Abstract P3-253, 9:30 a.m. \u2013 4:15 p.m. BST)\n      <\/li>\n<\/ul>\n<p>\n      <i>Wednesday, July 19<\/i>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Health Care Use Among Newly Diagnosed AD Patients in a U.S. Database<br \/>\n        of Employer-Sponsored Medicare Supplement Insurance Plans (Poster<br \/>\n        presentation, Abstract P4-358, 9:30 a.m. \u2013 4:15 p.m. BST)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        An Analytic Method to Address the Non-Linearity Form of AD Modifying<br \/>\n        Model (Poster presentation, Abstract P4-204, 9:30 a.m. \u2013 4:15 p.m. BST)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Potentiation of Tau Pathology By the ApoE\u03b54 Dementia Risk Allele<br \/>\n        (Poster presentation, Abstract P4-111, 9:30 AM \u2013 4:15 PM BST)\n      <\/li>\n<\/ul>\n<p>\n      <i>Thursday, July 20<\/i>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Leveraging Medicare Claims to Characterize Diagnostic Pathways in AD<br \/>\n        (Oral presentation, Abstract O5-03-03, 12:15 p.m. \u2013 12:30 p.m. BST)\n      <\/li>\n<\/ul>\n<p>\n      For more information, including a list of abstract titles, please visit: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alz.org%2Faaic%2F&amp;esheet=51589660&amp;newsitemid=20170717005295&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.alz.org%2Faaic%2F&amp;index=1&amp;md5=36c750033717e67c4b0a51c01b14aba8\" rel=\"nofollow\">https:\/\/www.alz.org\/aaic\/<\/a>.\n    <\/p>\n<p>\n      <b>About Merck\u2019s Commitment to Alzheimer\u2019s Disease<\/b>\n    <\/p>\n<p>\n      For more than 10 years, Merck has been researching different ways to<br \/>\n      treat Alzheimer\u2019s disease. In addition to our dedicated internal<br \/>\n      research efforts, we are driving innovation in collaboration with others<br \/>\n      and leveraging the latest innovations in brain imaging technology in<br \/>\n      order to help identify individuals in the early stages of Alzheimer\u2019s<br \/>\n      disease. Merck is working to improve our understanding of the disease to<br \/>\n      help those living with Alzheimer\u2019s and their loved ones around the world.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51589660&amp;newsitemid=20170717005295&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=5dec0171eadd85b571766341dd43e7ea\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and\u00a0connect with us on\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51589660&amp;newsitemid=20170717005295&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=a4ed89aa56fa4fba0adfa9f6bf7abc18\" rel=\"nofollow\">Twitter<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51589660&amp;newsitemid=20170717005295&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=98e2510082361df7cbbc9e6643f066ae\" rel=\"nofollow\">Facebook<\/a>,\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51589660&amp;newsitemid=20170717005295&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=3a3b9079e9ac6e9e25605e7b4e91592d\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51589660&amp;newsitemid=20170717005295&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=a023c3cd1c54e03e17c0a270865a8cb5\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and\u00a0<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51589660&amp;newsitemid=20170717005295&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=67ced4b1b5c3eb59ca3f6a5e55a6d186\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51589660&amp;newsitemid=20170717005295&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=c4bc5fafd49157637c259da89c548ebe\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170717005295r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Ian        McConnell, 973-901-5722<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of data at The Alzheimer\u2019s Association International Conference taking place in London, July 16\u201320, 2017. &#8220;Alzheimer\u2019s disease remains one of the most daunting medical issues of our time \u2013for individuals and their families, for the scientific and medical communities, and for public health,\u201d said Darryle Schoepp, vice president, neuroscience discovery, Merck Research Laboratories. &#8220;Merck has extensive research underway to develop novel medicines for Alzheimer\u2019s disease, and to improve understanding of the science and impact of this devastating disease.&#8221; Notable abstracts to be presented at The Alzheimer\u2019s Association International Conference \u00ae include: Saturday, July 15 First Evaluation of the Neurofibrillary Tangles Radioligand [18F]MK-6240 in AD Patients (Poster presentation, Abstract IC-P-177, 12:15 p.m. \u2013 1:30 p.m. BST) In Vitro Binding Studies to Evaluate the NFT-Specificity of<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745523","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Presentations of Clinical and Real-World Data at The Alzheimer\u2019s Association International Conference\u00ae - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentations-of-clinical-and-real-world-data-at-the-alzheimers-association-international-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Presentations of Clinical and Real-World Data at The Alzheimer\u2019s Association International Conference\u00ae - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of data at The Alzheimer\u2019s Association International Conference taking place in London, July 16\u201320, 2017. &quot;Alzheimer\u2019s disease remains one of the most daunting medical issues of our time \u2013for individuals and their families, for the scientific and medical communities, and for public health,\u201d said Darryle Schoepp, vice president, neuroscience discovery, Merck Research Laboratories. &quot;Merck has extensive research underway to develop novel medicines for Alzheimer\u2019s disease, and to improve understanding of the science and impact of this devastating disease.&quot; Notable abstracts to be presented at The Alzheimer\u2019s Association International Conference \u00ae include: Saturday, July 15 First Evaluation of the Neurofibrillary Tangles Radioligand [18F]MK-6240 in AD Patients (Poster presentation, Abstract IC-P-177, 12:15 p.m. \u2013 1:30 p.m. BST) In Vitro Binding Studies to Evaluate the NFT-Specificity of\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentations-of-clinical-and-real-world-data-at-the-alzheimers-association-international-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentations-of-clinical-and-real-world-data-at-the-alzheimers-association-international-conference\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentations-of-clinical-and-real-world-data-at-the-alzheimers-association-international-conference\\\/\",\"name\":\"Merck Announces Presentations of Clinical and Real-World Data at The Alzheimer\u2019s Association International Conference\u00ae - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-07-17T06:00:00+00:00\",\"dateModified\":\"2025-11-07T06:26:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentations-of-clinical-and-real-world-data-at-the-alzheimers-association-international-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentations-of-clinical-and-real-world-data-at-the-alzheimers-association-international-conference\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-presentations-of-clinical-and-real-world-data-at-the-alzheimers-association-international-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Presentations of Clinical and Real-World Data at The Alzheimer\u2019s Association International Conference\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Presentations of Clinical and Real-World Data at The Alzheimer\u2019s Association International Conference\u00ae - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentations-of-clinical-and-real-world-data-at-the-alzheimers-association-international-conference\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Presentations of Clinical and Real-World Data at The Alzheimer\u2019s Association International Conference\u00ae - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of data at The Alzheimer\u2019s Association International Conference taking place in London, July 16\u201320, 2017. \"Alzheimer\u2019s disease remains one of the most daunting medical issues of our time \u2013for individuals and their families, for the scientific and medical communities, and for public health,\u201d said Darryle Schoepp, vice president, neuroscience discovery, Merck Research Laboratories. \"Merck has extensive research underway to develop novel medicines for Alzheimer\u2019s disease, and to improve understanding of the science and impact of this devastating disease.\" Notable abstracts to be presented at The Alzheimer\u2019s Association International Conference \u00ae include: Saturday, July 15 First Evaluation of the Neurofibrillary Tangles Radioligand [18F]MK-6240 in AD Patients (Poster presentation, Abstract IC-P-177, 12:15 p.m. \u2013 1:30 p.m. BST) In Vitro Binding Studies to Evaluate the NFT-Specificity of","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentations-of-clinical-and-real-world-data-at-the-alzheimers-association-international-conference\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:24+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentations-of-clinical-and-real-world-data-at-the-alzheimers-association-international-conference\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentations-of-clinical-and-real-world-data-at-the-alzheimers-association-international-conference\/","name":"Merck Announces Presentations of Clinical and Real-World Data at The Alzheimer\u2019s Association International Conference\u00ae - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-07-17T06:00:00+00:00","dateModified":"2025-11-07T06:26:24+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentations-of-clinical-and-real-world-data-at-the-alzheimers-association-international-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentations-of-clinical-and-real-world-data-at-the-alzheimers-association-international-conference\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-presentations-of-clinical-and-real-world-data-at-the-alzheimers-association-international-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Presentations of Clinical and Real-World Data at The Alzheimer\u2019s Association International Conference\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"e720ed61-b56e-4f41-b1bf-568667a2b35a","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745523","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745523\/revisions"}],"predecessor-version":[{"id":3674877,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745523\/revisions\/3674877"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745523"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745523"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}